脊椎手術における出血制御のためのコラーゲンベーストロンビン止血剤の研究
脊椎手術におけるコラーゲン基質トロンビン含有止血剤の適用による止血効果を評価する無作為化臨床試験
This clinical trial evaluated the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compared this investigational product with an existing hemostatic agent to assess whether it performed equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who required spinal surgery were enrolled. The hemostat was applied intraoperatively when grade 3 bleeding was observed. The study assessed hemostatic performance and safety of the product when used during surgery.
調査の概要
詳細な説明
This was a randomized, single-blind, active-controlled clinical trial designed to assess the non-inferiority of a collagen-based thrombin-containing topical hemostat (CollaStat) compared to an existing hemostatic agent (Floseal) in patients undergoing spinal surgery. The investigational product was designed to be highly biocompatible to reduce adverse effects in case of in-body residue after application. Patients who underwent spinal surgery due to spinal stenosis, tumors, or trauma were enrolled and randomized in a 1:1 ratio. The hemostatic products were applied intraoperatively at bleeding sites classified as grade 3. For grade 4 or 5 bleeding, temporary hemostatic procedures were performed first to reduce bleeding intensity before applying the assigned hemostat. The study's primary endpoint was the hemostasis success rate, defined as the achievement of hemostasis within 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes of product application without additional intervention. Secondary outcomes included time to hemostasis, number of hemostatic units used per patient, volume of postoperative surgical drainage, length of hospital stay, incidence of intraoperative rebleeding, occurrence of postoperative hematoma or surgical site infection, and overall hemostatic effect assessed across all treated bleeding sites.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Gangnam-gu
-
Seoul、Gangnam-gu、韓国、06273
- Gangnam Severance Hospital
-
-
Giheung-gu
-
Yongin-si、Giheung-gu、韓国、16995
- Yongin Severance Hospital
-
-
Seodaemun-gu
-
Seoul、Seodaemun-gu、韓国、03722
- Severance Hospital, Yonsei University Health Syetem
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- An individual who has voluntarily signed the written consent form for participating in the research as a trial subject
- Patients aged 20 or older
- Patients who are able to participate throughout the entire clinical trial period
- Patient scheduled to have spinal surgery due to spinal stenosis, spinal tumor, injury, etc.
- Patients for whom hemostasis is difficult to achieve using standard procedures
- Patients with grade 3 or higher bleeding * Grade 4 or 5 bleeding is reduced to grade 3 by normal procedures (compression, sutures, electrosurgical scalpel, etc.).
Exclusion Criteria:
- Pregnant women or those planning to become pregnant within 1 month after application of the collagen-based hemostat
- Individuals with hypersensitivity to bovine-, porcine-, or animal-derived materials
- Individuals deemed inappropriate for participation by the investigators
- Patients who are using treatments that may affect the test results
- Patients with active infections at the surgical site
- Patients with contraindications to the use of local hemostatic materials
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Study Group
Group applied with CollaStat® |
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the study group is treated with Dalim Tissen's CollaStat® and compressed with general gauze. |
|
アクティブコンパレータ:Control Group
Group applied with Floseal® |
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the control group is treated with Baxter's Floseal® and compressed with general gauze |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hemostasis success rate
時間枠:Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes
|
After applying the haemostatic agent to the bleeding site, gentle compression is performed using surgical gauze. After lifting the gauze and washing off the excess hemostatic agent, check if hemostasis is maintained |
Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
指標出血部位における再出血の存在
時間枠:最初の適用(来院2回目;手術当日)からフォローアップ終了(術後最大8週間)まで
|
最初の適用(来院2回目;手術当日)からフォローアップ終了(術後最大8週間)まで
|
|
|
Time to hemostasis
時間枠:Intraoperation
|
Record the time point when hemostasis is achieved. |
Intraoperation
|
|
Number of hemostats used
時間枠:Intraoperation
|
Record the number of hemostats used until hemostasis. |
Intraoperation
|
|
Length of Hospital Stay
時間枠:From the date of surgical operation (Visit 2) until the date of hospital discharge, assessed up to 1 week (±3 days) after surgery
|
Length of hospital stay is defined as the number of days from the date of surgery (Visit 2) to the date of hospital discharge. |
From the date of surgical operation (Visit 2) until the date of hospital discharge, assessed up to 1 week (±3 days) after surgery
|
|
Incidence of adverse events
時間枠:From first application of the investigational medical device through end of follow-up (up to 8 weeks post-surgery)
|
Adverse events include hematoma and infection. |
From first application of the investigational medical device through end of follow-up (up to 8 weeks post-surgery)
|
|
Drain amount
時間枠:3 days after surgery
|
Record the drain amount until the 3rd postoperative day. |
3 days after surgery
|
|
Evaluation of Handling Characteristics (as Assessed by the Surgeon)
時間枠:Intraoperative
|
Hemostasis will be assessed intraoperatively at all treated bleeding sites after application of the investigational product (IP). Only the assigned IP should be used for the same patient. |
Intraoperative
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- DRT-CS01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Undecided. The plan for sharing individual participant data has not yet been determined.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。